You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,043,213


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,043,213
Title: Drug composition comprising albumin as active ingredient
Abstract:The present invention provides a pharmaceutical composition for treatment of corneal and conjunctival lesion, and dry eye comprising albumin as an active ingredient. The pharmaceutical composition is also useful for increase of eye surface epithelium mucin secretion. The present invention further provides a method for treatment of corneal and conjunctival lesion, and dry eye, which comprises administering, to a subject in need of such treatment, albumin in an amount effective. In addition, the present invention provides a use of albumin for manufacture of a pharmaceutical composition of the present invention.
Inventor(s): Tsubota; Kazuo (Funabashi, JP)
Assignee: R-Tech Ueno, Ltd. (Osaka, JP)
Application Number:08/981,229
Patent Claims:1. A method for treatment of dry eye which comprises administering, to a subject in need of such treatment, albumin in an amount effective for treatment of dry eye.

2. The method according to claim 1, wherein the said albumin is human origin albumin.

3. The method according to claim 1, wherein the said albumin is administered in the form of eye drops.

4. The method according to claim 1, which comprises administering a pharmaceutical composition containing 1 to 1000 mg/ml of albumin and pharmaceutically acceptable carrier.

5. A method for increasing eye surface epithelium mucin secretion, which comprises administering, to a subject in need of such administration, albumin in an amount effective for increasing eye surface epithelium mucin secretion.

6. The method according to claim 5, wherein the said albumin is human origin albumin.

7. The method according to claim 5, wherein the said albumin is administered in the form of eye drops.

8. The method according to claim 5, which comprises administering a pharmaceutical composition containing 1 to 1000 mg/ml of albumin and pharmaceutically acceptable carrier.

Details for Patent 6,043,213

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2016-04-19
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2016-04-19
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2016-04-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.